Ben L. Da
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ben L. Da has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Sanjaya Kumar Satapathy
Department of Medicine, North Shore University Hospital/Northwell Health, Manhasset, New York, USA
6 shared publications - Christopher Koh
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
4 shared publications Christopher Koh
Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD
3 shared publicationsPallavi Surana
Liver Diseases Branch National Institute of Diabetes & Digestive & Kidney Diseases National Institutes of Health Bethesda MD USA
3 shared publicationsTheo Heller
Liver Diseases Branch National Institute of Diabetes & Digestive & Kidney Diseases National Institutes of Health Bethesda MD USA
3 shared publications- Theo Heller
Translational Hepatology Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (3) , 256-261
Acetaminophen toxicity: Patterns of liver injury and effect on hospital length of stay, and need for inpatient psychiatric care
Background and Aim: Acetaminophen toxicity is the most common cause of acute liver failure (ALF) in the United States. Among patients with acetaminophen toxicity, a vast majority have intentional overdose and concurrent psychiatric comorbidities. We aimed to analyze patient characteristics, patterns of overdose, and outcomes in patients with acetaminophen overdose at our liver transplantation (LT) center. Materials and Methods: Patients ≥18 years of age with acetaminophen overdose between 2011 and 2020 at our institution were identified. Patient demographics, clinical and laboratory data, patterns of overdose (intentional vs. unintentional), psychiatric comorbidities, need for admission to inpatient psychiatry service, transplant wait listing, need for transplantation, and death were assessed. Categorical variables are presented as counts with percentages, continuous variables as median with interquartile range IQR (Q1-Q3), and p
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (3) , 256-261
Open AccessAcetaminophen toxicity: Patterns of liver injury and effect on hospital length of stay, and need for inpatient psychiatric care
Background and Aim: Acetaminophen toxicity is the most common cause of acute liver failure (ALF) in the United States. Among patients with acetaminophen toxicity, a vast majority have intentional overdose and concurrent psychiatric comorbidities. We aimed to analyze patient characteristics, patterns of overdose, and outcomes in patients with acetaminophen overdose at our liver transplantation (LT) center. Materials and Methods: Patients ≥18 years of age with acetaminophen overdose between 2011 and 2020 at our institution were identified. Patient demographics, clinical and laboratory data, patterns of overdose (intentional vs. unintentional), psychiatric comorbidities, need for admission to inpatient psychiatry service, transplant wait listing, need for transplantation, and death were assessed. Categorical variables are presented as counts with percentages, continuous variables as median with interquartile range IQR (Q1-Q3), and p
- 22 October 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (6) , 2147-2157
Clinical trials in hepatitis D virus: Measuring success
Chronic hepatitis D infection results in the most severe form of chronic viral hepatitis but currently lacks effective treatment options. Therapy with pegylated interferon alpha is recommended for finite treatment duration by major liver societies. Still, it is plagued by low rates of sustained virologic response (SVR) and frequent relapses even if SVR is achieved. Recently, a wave of investigational therapies has come under evaluation, including bulevirtide, lonafarnib, pegylated interferon lambda, and REP‐2139 creating excitement with this viral infection. However, there has been significant variability in the endpoints used to evaluate these therapeutics. One of the recently introduced endpoints is characterized by a decline in HDV RNA by 2 logs, with or without achieving an undetectable serum hepatitis D virus (HDV) RNA, as a marker of virologic response. Furthermore, this measure has been combined with alanine aminotransferase normalization, also known as a biochemical response, to formulate the primary endpoint of several late‐stage studies. Per recent guidance by the US Food and Drug Administration, these should be surrogate endpoints that will ultimately portend long‐term clinical benefits. These clinical benefits may include reducing the risk of progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, and mortality. However, the optimal way to measure success in HDV clinical trials remains unknown and will continue to evolve.
- 22 October 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (6) , 2147-2157
Clinical trials in hepatitis D virus: Measuring success
Chronic hepatitis D infection results in the most severe form of chronic viral hepatitis but currently lacks effective treatment options. Therapy with pegylated interferon alpha is recommended for finite treatment duration by major liver societies. Still, it is plagued by low rates of sustained virologic response (SVR) and frequent relapses even if SVR is achieved. Recently, a wave of investigational therapies has come under evaluation, including bulevirtide, lonafarnib, pegylated interferon lambda, and REP‐2139 creating excitement with this viral infection. However, there has been significant variability in the endpoints used to evaluate these therapeutics. One of the recently introduced endpoints is characterized by a decline in HDV RNA by 2 logs, with or without achieving an undetectable serum hepatitis D virus (HDV) RNA, as a marker of virologic response. Furthermore, this measure has been combined with alanine aminotransferase normalization, also known as a biochemical response, to formulate the primary endpoint of several late‐stage studies. Per recent guidance by the US Food and Drug Administration, these should be surrogate endpoints that will ultimately portend long‐term clinical benefits. These clinical benefits may include reducing the risk of progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, and mortality. However, the optimal way to measure success in HDV clinical trials remains unknown and will continue to evolve.
- Open Access
- 10 August 2022
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 12 (S1) , S5-S14
Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts
Graft macrosteatosis can predispose to a higher risk of graft loss so we sought to redefine acceptable cutoffs for graft steatosis. Data of 26,103 donors who underwent liver transplantation (LT) between January 2004 and December 2018 from the UNOS-STAR database were utilized. A high-risk steatotic (HRS) graft and a low-risk steatotic (LRS) graft were defined as ≥20% and <20% macrosteatosis, respectively. High-risk steatotic grafts were further classified as grafts with 20–29% (G1S grafts), 30–39% (G2S grafts), and ≥40% steatosis (G3S grafts). Outcomes between groups were compared. LRS grafts had excellent graft (93.3 and 87.7%) and overall survival (95.4 and 90.5%) at 90 days and 1 year. Compared to LRS grafts, G1S, G2S, and G3S grafts had worse graft and overall survival at 90 days and 1-year (p <0.001). There was no difference in graft or overall survival of G1S or G3S grafts compared to G2S grafts until after adjustment in which G3S grafts were found to be associated with an increased risk of graft loss—aHR 1.27 (1.03–1.57), p = 0.02. Liver grafts can be categorized into three categories: (1) <20% or “very low risk”, (2) 20–39% or “low-to-moderate risk”, and usually acceptable, and (3) ≥40% steatosis or “moderate-to-high risk”. Da BL, Satiya J, Heda RP, et al. Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S5–S14.
- 10 August 2022
- Published by Jaypee Brothers Medical Publishing in Euroasian Journal of Hepato-Gastroenterology
- Vol. 12 (S1) , S5-S14
Open AccessOutcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts
Graft macrosteatosis can predispose to a higher risk of graft loss so we sought to redefine acceptable cutoffs for graft steatosis. Data of 26,103 donors who underwent liver transplantation (LT) between January 2004 and December 2018 from the UNOS-STAR database were utilized. A high-risk steatotic (HRS) graft and a low-risk steatotic (LRS) graft were defined as ≥20% and <20% macrosteatosis, respectively. High-risk steatotic grafts were further classified as grafts with 20–29% (G1S grafts), 30–39% (G2S grafts), and ≥40% steatosis (G3S grafts). Outcomes between groups were compared. LRS grafts had excellent graft (93.3 and 87.7%) and overall survival (95.4 and 90.5%) at 90 days and 1 year. Compared to LRS grafts, G1S, G2S, and G3S grafts had worse graft and overall survival at 90 days and 1-year (p <0.001). There was no difference in graft or overall survival of G1S or G3S grafts compared to G2S grafts until after adjustment in which G3S grafts were found to be associated with an increased risk of graft loss—aHR 1.27 (1.03–1.57), p = 0.02. Liver grafts can be categorized into three categories: (1) <20% or “very low risk”, (2) 20–39% or “low-to-moderate risk”, and usually acceptable, and (3) ≥40% steatosis or “moderate-to-high risk”. Da BL, Satiya J, Heda RP, et al. Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S5–S14.
- 20 May 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (4) , E78-E79
Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC
- 20 May 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 76 (4) , E78-E79
Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC
- Open Access
- 20 October 2021
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 6 (3) , 550-560
Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis
In order to determine the relationship between socioeconomic deprivation and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), we retrospectively reviewed the electronic medical records of 1,430 patients in a large tertiary health care network in New York. These patients underwent liver biopsy over a 10‐year period and were included in our study if they had evidence of NAFLD/NASH on liver biopsy. Zip codes were used to obtain data necessary to derive the social deprivation index (SDI) from the US Bureau of the Census. The high‐SDI group was compared to the low‐SDI group. Univariate and multivariate logistic regressions were performed to assess association between socioeconomic factors and NAFLD parameters, including presence of NASH (NAFLD activity score >4), moderate to severe steatosis (>33%), and significant fibrosis (S2‐S4). We included 614 patients with NAFLD/NASH; the median SDI was 31.5. Hemoglobin A1c values were higher in the high‐SDI group compared to the low‐SDI group (6.46 vs. 6.12, P = 0.02). Socioeconomic factors, such as private versus public health care, percentage being foreign born, percentage without a car, percentage with higher needs (65 years old), and percentage currently living in renter‐occupied and crowded housing units, showed statistically significant associations in predicting NASH. After adjusting for patient age, sex, race, body mass index, and diabetes, we saw a significant association between four or more socioeconomic parameters in predicting NASH (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.099‐2.856; P = 0.0190) and six or more socioeconomic parameters in predicting severe steatosis (OR, 1.498; 95% CI, 1.031‐2.176; P = 0.0338) but no significant correlation between the number of socioeconomic parameters and significant fibrosis. Conclusion: Greater number of socioeconomic determinants (four or more) are associated with greater severity of NASH. Awareness of NAFLD/NASH needs to be raised in communities with high socioeconomic deprivation.
- 20 October 2021
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 6 (3) , 550-560
Open AccessCommunity Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis
In order to determine the relationship between socioeconomic deprivation and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), we retrospectively reviewed the electronic medical records of 1,430 patients in a large tertiary health care network in New York. These patients underwent liver biopsy over a 10‐year period and were included in our study if they had evidence of NAFLD/NASH on liver biopsy. Zip codes were used to obtain data necessary to derive the social deprivation index (SDI) from the US Bureau of the Census. The high‐SDI group was compared to the low‐SDI group. Univariate and multivariate logistic regressions were performed to assess association between socioeconomic factors and NAFLD parameters, including presence of NASH (NAFLD activity score >4), moderate to severe steatosis (>33%), and significant fibrosis (S2‐S4). We included 614 patients with NAFLD/NASH; the median SDI was 31.5. Hemoglobin A1c values were higher in the high‐SDI group compared to the low‐SDI group (6.46 vs. 6.12, P = 0.02). Socioeconomic factors, such as private versus public health care, percentage being foreign born, percentage without a car, percentage with higher needs (65 years old), and percentage currently living in renter‐occupied and crowded housing units, showed statistically significant associations in predicting NASH. After adjusting for patient age, sex, race, body mass index, and diabetes, we saw a significant association between four or more socioeconomic parameters in predicting NASH (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.099‐2.856; P = 0.0190) and six or more socioeconomic parameters in predicting severe steatosis (OR, 1.498; 95% CI, 1.031‐2.176; P = 0.0338) but no significant correlation between the number of socioeconomic parameters and significant fibrosis. Conclusion: Greater number of socioeconomic determinants (four or more) are associated with greater severity of NASH. Awareness of NAFLD/NASH needs to be raised in communities with high socioeconomic deprivation.
- Open Access
- 30 March 2021
- Published by Wiley in Journal of Internal Medicine
- Vol. 290 (2) , 470-472
Cholestatic liver injury in COVID‐19 is a rare and distinct entity and is associated with increased mortality
Current evidence indicates that the development of acute hepatocellular liver injury during coronavirus disease 2019 (COVID‐19) is associated with more severe COVID‐19 disease.[1] Since SARS‐CoV2 is able to enter the liver via the ACE2 receptor proteins located on the epithelium of bile ducts, direct viral cholangiocyte injury is theoretically a possible pathogenic mechanism of the virus resulting in cholestatic liver injury.[2] Supporting this idea: a recent meta‐analysis that reported serum alkaline phosphatase (ALP) elevations occurs in up to 13.7% of patients[3], a case series describing the clinical/histologic features of three patients with COVID‐19 cholangiopathy[4], and a recent study reporting higher fatality rates in COVID‐19 patients with cholestasis.[5]
- 30 March 2021
- Published by Wiley in Journal of Internal Medicine
- Vol. 290 (2) , 470-472
Open AccessCholestatic liver injury in COVID‐19 is a rare and distinct entity and is associated with increased mortality
Current evidence indicates that the development of acute hepatocellular liver injury during coronavirus disease 2019 (COVID‐19) is associated with more severe COVID‐19 disease.[1] Since SARS‐CoV2 is able to enter the liver via the ACE2 receptor proteins located on the epithelium of bile ducts, direct viral cholangiocyte injury is theoretically a possible pathogenic mechanism of the virus resulting in cholestatic liver injury.[2] Supporting this idea: a recent meta‐analysis that reported serum alkaline phosphatase (ALP) elevations occurs in up to 13.7% of patients[3], a case series describing the clinical/histologic features of three patients with COVID‐19 cholangiopathy[4], and a recent study reporting higher fatality rates in COVID‐19 patients with cholestasis.[5]
- Open Access
- 1 December 2020
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (12) , e2027551
Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation
Despite an increase in the number of liver transplants (LTs) performed in the United States, the rate at which patients are placed on the waitlist continues to surpass the increased number of transplants, creating a significant mismatch between organ supply and demand.1 The use of hepatitis C virus (HCV)–positive organs has been widely adopted as one of the solutions to the major organ shortage by increasing the donor pool.2 Although HCV infection is estimated to affect 1% to 2% of the general US population, this risk is higher (3%-18%) among organ donors with increased risk as defined by the Public Health Service.3 In light of the ongoing opioid epidemic and the associated rise in drug overdose deaths, the number of Public Health Service “increased risk” HCV-positive organs available has been increasing rapidly.4,5
- 1 December 2020
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (12) , e2027551
Open AccessDonor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation
Despite an increase in the number of liver transplants (LTs) performed in the United States, the rate at which patients are placed on the waitlist continues to surpass the increased number of transplants, creating a significant mismatch between organ supply and demand.1 The use of hepatitis C virus (HCV)–positive organs has been widely adopted as one of the solutions to the major organ shortage by increasing the donor pool.2 Although HCV infection is estimated to affect 1% to 2% of the general US population, this risk is higher (3%-18%) among organ donors with increased risk as defined by the Public Health Service.3 In light of the ongoing opioid epidemic and the associated rise in drug overdose deaths, the number of Public Health Service “increased risk” HCV-positive organs available has been increasing rapidly.4,5
- Open Access
- 16 October 2020
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 5 (2) , 177-188
Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6
Liver injury is commonly seen in coronavirus disease 2019 (COVID-19); however, the mechanism behind liver injury, particularly in patients with severe and critical COVID-19, remains unclear, and the clinical course is poorly described. We conducted a single-center retrospective cohort study of consecutive patients hospitalized with severe and critical COVID-19 with or without liver injury and who underwent immunologic testing (interleukin [IL]-6, IL-8, tumor necrosis factor alpha [TNF-α], and IL-1β). Liver injury was defined as peak aminotransferases ≥3 times the upper limit of normal (40 U/L) or ≥120 U/L. Patients with liver injury were compared to those who had normal aminotransferases throughout the hospital course. We studied 176 patients: 109 with liver injury and 67 controls. Patients with liver injury were more likely to be men (71.6% vs. 37.3%, P < 0.001). Peak inflammatory markers and IL-6 were higher in the liver injury group: C-reactive protein (CRP), 247 vs. 168 mg/L, P < 0.001; lactate dehydrogenase (LDH), 706 vs. 421 U/L; ferritin, 2,973 vs. 751 ng/mL, P < 0.001; IL-6, 121.0 vs. 71.8 pg/mL, P < 0.001. There was no difference in the levels of IL-8, TNF-α, and IL-1β. The liver injury group had a longer length of stay in the hospital and more severe COVID-19 despite having less diabetes and chronic kidney disease. Conclusion: An exaggerated hyperinflammatory response (cytokine storm) characterized by significantly elevated CRP, LDH, ferritin, and IL-6 levels and increasing severity of COVID-19 appears to be associated with the occurrence of liver injury in patients with severe/critical COVID-19.
- 16 October 2020
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 5 (2) , 177-188
Open AccessLiver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6
Liver injury is commonly seen in coronavirus disease 2019 (COVID-19); however, the mechanism behind liver injury, particularly in patients with severe and critical COVID-19, remains unclear, and the clinical course is poorly described. We conducted a single-center retrospective cohort study of consecutive patients hospitalized with severe and critical COVID-19 with or without liver injury and who underwent immunologic testing (interleukin [IL]-6, IL-8, tumor necrosis factor alpha [TNF-α], and IL-1β). Liver injury was defined as peak aminotransferases ≥3 times the upper limit of normal (40 U/L) or ≥120 U/L. Patients with liver injury were compared to those who had normal aminotransferases throughout the hospital course. We studied 176 patients: 109 with liver injury and 67 controls. Patients with liver injury were more likely to be men (71.6% vs. 37.3%, P < 0.001). Peak inflammatory markers and IL-6 were higher in the liver injury group: C-reactive protein (CRP), 247 vs. 168 mg/L, P < 0.001; lactate dehydrogenase (LDH), 706 vs. 421 U/L; ferritin, 2,973 vs. 751 ng/mL, P < 0.001; IL-6, 121.0 vs. 71.8 pg/mL, P < 0.001. There was no difference in the levels of IL-8, TNF-α, and IL-1β. The liver injury group had a longer length of stay in the hospital and more severe COVID-19 despite having less diabetes and chronic kidney disease. Conclusion: An exaggerated hyperinflammatory response (cytokine storm) characterized by significantly elevated CRP, LDH, ferritin, and IL-6 levels and increasing severity of COVID-19 appears to be associated with the occurrence of liver injury in patients with severe/critical COVID-19.